ホーム>>Signaling Pathways>> Immunology/Inflammation>> PGE synthase>>SAR191801

SAR191801

カタログ番号GC12330

SAR191801 は、蛍光偏光アッセイまたは EIA アッセイで 12 nM の IC50 を持つ hPGDS 阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

SAR191801 化学構造

Cas No.: 1234708-04-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$287.00
在庫あり
5mg
$215.00
在庫あり
10mg
$333.00
在庫あり
50mg
$1,103.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.IC50 value: 12 nMTarget: hPGDSThe detailed information please refer to WO2011044307A1 and WO2010080563A2

References:
[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.
[2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.
[3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 1967-1969.

レビュー

Review for SAR191801

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SAR191801

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.